The FDA is investigating a connection between diabetes drugs belonging to the Sodium-Glucose Co-Transporter-2 (SGLT2) inhibitors class of drugs and the following side effects: Diabetic Ketoacidosis (DKA) Ketoacidosis Ketosis Acute Kidney Injury Kidney Failure / Renal Failure Kidney Damage Pyelonephritis (kidney infection) … [Read more...]
Federal Court Invokana MDL In New Jersey With Judge Brian Martinotti
Invokana (canagliflozin) was approved by the FDA in 2013. Invokamet (canagliflozin and metformin) was approved by the FDA in 2014. Both of these drugs were approved for use by patients with Type 2 diabetes. In December 2015 the FDA issued this Drug Safety Communication: “FDA revises labels of SGLT2 inhibitors for diabetes to include warnings … [Read more...]
December 2016: FDA Requires Safety Warnings Label Change For Jardiance
After the December 2, 2016 decision by the FDA decision by U.S. regulators to expand the health benefits for the relatively new diabetes medicine Jardiance (empagliflozin) to include preventing fatal heart attacks and strokes in type 2 diabetes patients, we saw news reports about its expected effect on Jardiance sales in the U.S. From this … [Read more...]
Farxiga / Jardiance / Invokana: Label Change Adds Ketoacidosis Warning
In August 2016 the FDA sent letters to Janssen Pharmaceuticals and AstraZeneca Pharmaceuticals for label changes about fatal cases of ketoacidosis cases involving Invokana (canagliflozin), Invokamet (canagliflozin and metformin), Farxiga (dapagliflozin), and Xigduo XR (dapagliflozin and metformin extended-release). As for the other diabetes … [Read more...]
Viagra, Nexium, And Invokana: Drug Injury Lawsuits Report: Summer 2016
We are currently investigating possible drug injury lawsuits against the responsible pharmaceutical companies for patients who used the drugs listed below and developed certain side effects. (1) Erectile Dysfunction (ED) Pills, Benign Prostatic Hyperplasia (BPH) Medicines, and Pulmonary Arterial Hypertension (PAH) Medications in the … [Read more...]
Invokana / Farxiga / Jardiance: UTIs Then Urosepsis And Pyelonephritis
To date, most attention has been directed to the association between the sodium-glucose cotransporter-2 (SGLT2) inhibitors drugs and diabetic ketoacidosis (DKA). More recently, there was an FDA announcement concerning a label change about the acute kidney injury side effect. What has received less attention, it seems, is the fact that these … [Read more...]
Invokana / Farxiga / Jardiance: Amputations; Lactic Acidosis; Ketoacidosis
In July 2016 Boehringer Ingelheim Pharmaceuticals, Inc. received a Supplemental Approval letter from the FDA concerning a label change about fatal cases of ketoacidosis which have been reported concerning Jardiance, Synjardy, and Glyxambi. These relatively new diabetes medicines are part of the Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors … [Read more...]